tirzepatide and autoimmune disease GLP-1 Agonists in Shifting the Scales: Tirzepatide's Breakthrough

Since tirzepatide also promotes lower blood sugar, the combination requires monitoring for hypoglycemia

Glucagon receptor activation is believed to increase energy expenditure and may potentially support hepatic fat reduction, though these latter effects remain under investigation and have not yet been fully characterised in humans

GLP-1 medications are not recommended during pregnancy, and for semaglutide specifically, treatment should be stopped at least 2 months before planned conception due to its long half-life

Examples include glipizide (Glucotrol XL), glimepiride (Amaryl), glyburide (Micronase), pioglitazone (Actos), sitagliptin (Januvia), and others

[DOI] [PMC free article] [PubMed] [Google Scholar] 10.Patel AV, Jotwani PM, Lee TP